A landmark review of 54 randomized trials involving 2,477 participants found no significant benefit from cannabis-based treatments for mental health conditions like depression, anxiety, and PTSD. The research, led by the University of Sydney and published in The Lancet Psychiatry, concluded that routine use of medicinal cannabis is 'rarely justified,' with adverse effects 75% more likely.
While some promise was seen for insomnia, Tourette’s, and autistic traits, evidence quality remained low. Cannabinoids showed no meaningful impact on psychotic disorders, opioid use disorder, or anorexia nervosa.
Experts warn that using cannabis to manage emotional distress may delay access to proven therapies and increase risks of psychosis and dependence-especially in those with a personal or family history.
Despite its medical uses in epilepsy, multiple sclerosis, and pain, cannabis remains unproven for mental health treatment. Experts urge users to monitor mood changes, avoid reliance, and seek professional support when needed.
The study's limitations include high risk of bias in nearly half the trials and variability in products, doses, and real-world usage patterns.